Kura Oncology (KURA) Capital Expenditures (2014 - 2026)
Kura Oncology (KURA) posted quarterly Capital Expenditures of $128000.0 for Q1 2026, down 56.16% year-over-year from $292000.0 in Q1 2025, and down 94.49% quarter-over-quarter from $2.3 million in Q4 2025.
Kura Oncology (KURA) Capital Expenditures (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Capital Expenditures for 13 consecutive years, with $128000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 56.16% year-over-year to $128000.0; the TTM figure through Mar 2026 stood at $6.5 million (up 852.06% YoY), while the FY2025 annual figure was $6.6 million, up 1306.36% from the prior year.
- Capital Expenditures eased to $128000.0 in Q1 2026 per KURA's latest filing, from $2.3 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.6 million in Q3 2025 and bottomed at $12000.0 in Q4 2022.
- Historically, Capital Expenditures has averaged $502000.0 across 5 years, with a median of $112000.0 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures plunged 97.01% — and 2025, when it soared 9012.5%.
- Kura Oncology's Capital Expenditures stood at $12000.0 in 2022, then jumped by 33.33% to $16000.0 in 2023, then surged by 2225.0% to $372000.0 in 2024, then jumped by 523.92% to $2.3 million in 2025, then sank by 94.49% to $128000.0 in 2026.
- Business Quant data shows KURA's Capital Expenditures at $128000.0 in Q1 2026, $2.3 million in Q4 2025, and $2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 656,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 656,000.00 |
| Jun 30, 2026 | 656,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Dec 31, 2025 | 2.32 Mn |
| Dec 31, 2025 | 2.32 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Sep 30, 2025 | 2.57 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.46 Mn |
| Mar 31, 2025 | 292,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Dec 31, 2024 | 372,000.00 |
| Dec 31, 2024 | 372,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Jun 30, 2024 | 16,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 16,000.00 |
| Dec 31, 2023 | 16,000.00 |